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INTRODUCTION 
 
 
Normal pregnancy is characterized by unique physiological changes. It is 
mandatory for an anesthesiologist to understand these changes and their anesthetic 
implications.  
 
Pregnancy induced hypertension (PIH) is a disorder of unknown etiology 
affecting 5-10% of all pregnancies characterized by the development of 
hypertension with proteinuria after 20 weeks of gestation. 
 
Hypertension-Sustained systolic pressure of at least 140mmHg or a 
sustained diastolic pressure of at least 90 mmHg that occurs after 20 weeks of 
gestation in a woman with previously normal blood pressure. 
 
  Maternal complications of severe pregnancy induced hypertension include 
pulmonary edema, intracerebral hemorrhage and renal failure. Fetal complications 
include intra uterine growth retardation (IUGR), perinatal mortality. 
 
Management of severe pregnancy induced hypertension requires 
multidisciplinary approach. 
 
Definitive treatment consists of termination of pregnancy along with 
prevention of seizures and control of blood pressure. 
 
1 
The drugs used in the control of blood pressure are oral antihypertensives 
like Alphamethyldopa and intravenous agents like Hydralazine, Labetalol, 
Nitroglycerin etc. 
 
  Intravenous Labetalol injection is a unique drug with both alpha and beta 
adrenergic receptor blocking properties. It has both blood pressure and heart rate 
reducing properties. This makes it a good choice in treating high blood pressure in 
severe pregnancy induced hypertension patients. Our study is to find out  the 
efficacy of intravenous Labetalol injection  in the acute preoperative control of 
high blood pressure in severe pregnancy induced hypertension (PIH) patients. 
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AIM OF STUDY 
 
 
The aim of this study is to find out and compare the efficacy of intravenous 
Labetalol injection with the routinely used regimen of oral antihypertensives  tablet 
Alphamethyldopa and tablet Nifedipine in the acute preoperative control of high 
blood pressure in severe pregnancy induced hypertension patients. 
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NORMAL PREGNANCY&PREGNANCY INDUCED HYPERTENSION 
 
Normal pregnancy is characterized by unique physiological changes. It is 
mandatory for an anesthesiologist to understand these changes and their anesthetic 
implications. 
 
PHYSIOLOGY OF NORMAL PREGNANCY  
 
CARDIOVASCULAR SYSTEM 
 
PARAMETER 
 
CHANGE AMOUNT 
Heart rate                   Increase 20 – 30 % 
Stroke volume                                        ,, 20 – 50 % 
Cardiac output                                      ,, 30 – 50% 
Central venous pressure                         - - 
Pulmonary capillary wedge pressure     - - 
Systemic vascular resistance    Decrease 20% 
Pulmonary vascular resistance      ,, 30% 
Systemic blood pressure                        ,, midtrimester10-     
15mmHg,then rises
                                                                                                                                                      
Supine hypotension syndrome 
 
Up to 10% of pregnant patients at term show signs of shock when assuming 
supine position.  
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Exacerbated By 
  
-  central neuraxial blockade 
- vasodilators 
- anesthetic agents 
 
Minimised by  
 
- left uterine displacement accomplished by keeping a wedge below right hip 
or tilting the table. 
 
Electrocardiography 
 
- Right axis deviation 
- Right bundle branch block 
- ST depression of 1mm on left precordial leads 
- T wave inversion L3, V2, 3 
- Rotation +/- 15 degrees (QRS axis) 
 
Echocardiography 
 
- Tricuspid regurgitation 
- Pulmonary regurgitation 
- Mitral regurgitation 
- Increased left ventricular end diastolic volume 
- Increased left atrial size 
 
Hematological system 
 
- Increase in blood volume by 45% 
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- Increase in red cell volume by 30% 
- So physiological anemia 
- All coagulation factors especially 1, 7 increased 
- Platelet count decreased in 3rd trimester 
 
 
Respiratory system 
    
Functional residual capacity    Decreased 20% 
Tidal volume                           Increased 50% 
Respiratory rate                      ,, 10 – 15 % 
Minute ventilation                  ,, 30 – 40 % 
PaCo2     30 mmHg 
 
- Pregnant mothers desaturate faster 
- In an emergency setting 4 maximum capacity breaths with 100% O2 should 
be sufficient  
- Edema, capillary engorgement of mucosa of airway is common 
 
Gastrointestinal system 
 
- Progesterone relaxes smooth muscle and impairs esophageal and intestinal 
motility 
- So increased risk of aspiration 
 
Central nervous system 
 
Increased sensitivity to local and general anaesthetics      
 
- Local anesthetic requirement reduced qualitatively and quantitatively 
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- Minimum alveolar concentration of Halothane decreased by 25% 
- Minimum alveolar concentration of Isoflurane decreased by 40% 
- Mechanism – progesterone induced sensitivity  
- Increased concentration of endogenous opioid ligands 
 
Renal system 
 
- Increased glomerular filtration rate (GFR) 
 
PARAMETER PREGNANT NON PREGNANT 
Creatinine clearance     140-160 ml/mt 90-110ml/mt 
Urea 2 – 4.5mmol/lt 6 – 7 m mol/lt 
Creatinine 25-75 micromol/lt 100micromol/lt 
PH 7.44 7.4 
HCO3 18-22 m mol/lt 23-26 m mol/lt 
 
- Glycosuria common due to increased glomerular filtration rate and reduced 
renal tubular absorption 
 
 
FETO-PLACENTO-UTERINE CIRCULATION 
 
- Uterine blood flow at term about 500 – 700 ml/mt 
- About 80% of uterine blood flows through intervillous space 
- 40 – 50 % of fetal cardiac output goes to placenta  
- Umbilical capillaries traverse the chorionic villus 
- Chorionic villi and intervillous spaces provide the interface for maternal and 
fetal circulation 
- Uterine blood flow lacks autoregulation so 
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Uterine blood flow  =  uterine arterial pressure – uterine venous Pressure 
                                               Uterine vascular resistance        
PROPOSED PATHOGENESIS OF PREGNANCY INDUCED 
HYPERTENSION 
 
 
 
 
SEVERE PREGNANCY INDUCED HYPERTENSION (PIH) 
 
Pregnancy induced hypertension (PIH) is a disorder of unknown etiology 
affecting 5-10% of all pregnancies. 
 
Definition- Development of hypertension with proteinuria after 20 weeks of 
gestation. 
 
Hypertension-Sustained systolic pressure of atleast 140mmHg or a sustained 
diastolic pressure of at least 90mmHg that occurs after 20 weeks of gestation in 
a woman with previously normal blood pressure. 
Proteinuria->300mgm in 24hour urine collection. 
 
Features of Pregnancy induced hypertension 
 
FACTORS MILD 
 
SEVERE 
 
Systolic blood pressure               <160mmHg >160mmHg 
Diastolic blood pressure              <110mmHg >110mmHg 
Urinary protein                           
 
<5gm/24hr   
Dipstick+or2+ 
>5gm/24hr 
Dipstick3+or4+ 
Headache                                       No Yes 
Visual disturbance                        No Yes 
Epigastric pain                              No Yes 
Right upper quadrant pain         No Yes 
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Pulmonary edema                         No Yes 
Cyanosis                                        No Yes 
HELLP                                          No Yes 
Platelet count               >100000/cumm <100000/cumm 
 
Risk factors 
 
Primi,teenage pregnancy,history of previous preeclampsia,family history,renal 
disease,chronic hypertension,obesity,diabetes mellitus,activated protein C 
resistance(factor V mutation),protein S deficiency,Anti phospholipid  antibody 
syndrome,hyperhomocysteinuria,smoking,stress,hydatiform mole.                   
 
PATHOGENESIS 
 
Immunologic features 
 
The fetus acquires 50% of its genes from the father thus it represents a 
paternal allograft that interacts with maternal tissue as fetal trophoblast migrates 
into the maternal deciduas after implantation. 
True intervillous blood flow is established at 12weeks gestation &in normal 
gestation a second wave of trophoblastic invasion occurs at 14-16 weeks gestation 
resulting in disruption of muscular integrity of the maternal spiral arteries, which 
leads to adrenergic denervation and converts them into low resistance vessels.  
At the same time biochemical adaptations occur in maternal vasculature with 
an increased dominance of endothelium dependant vasodilators prostaglandin 
PGI2 Nitric oxide (NO). 
In women with pregnancy induced hypertension a failure of secondary 
trophoblastic invasions of the deciduo-myometrial junction occurs. This failure  
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results in a high resistance, low flow utero placental circulation and consequent 
placental ischemia and hypoxia. These changes represent an aberrant 
immunological mechanism. Some women develop pregnancy induced 
hypertension (PIH), some women develop intra uterine growth retardation (IUGR). 
 
 
Genetic factors 
 
A molecular variant of angiotensinogen (Angiotensinogen gene T235) 
angotensinogen II type I Receptor. 
 
FactorV Leiden mutation leading to increase in resistance to activated 
protein C. 
 
Endothelial factors 
 
Vascular endothelium is a metabolically active interface between blood and 
underlying tissue. Vascular endothelial damage and dysfunction is the common 
pathological feature of Pregnancy induced hypertension and occurs in the placental 
decidual vessels and renal microvasculature.  
 
Platelet factors 
 
Platelet activation and aggregation leads to imbalance between vasodilators 
(Prostacyclin I2&Nitric oxide) and vasoconstrictors (thromboxane A2&5HT) 
 
Coagulation factors 
 
Vascular endothelial growth factor (VEGF) 
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MECHANSISAM OF ENDOTHELIAL DAMAGE LEADING TO PIH 
 
 
 
 
Pathophysiology 
 
Cardiovascular changes 
 
Blood pressure 
 
Flattening of normal diurnal blood pressure pattern  
Labile blood pressure. 
Blood volume reduced in some women  
Increased level of Atrial natriuretic peptide. 
 
Hemodynamic changes 
 
varied &complex 
changes with disease, pregnancy, therapy. 
Cardiac function 
Normal heart rate 
Central venous pressure is misleading 
Poor correlation between central venous pressure & pulmonary capillary 
wedge pressure. 
Large bolus of fluid to predetermined central venous pressure can lead to 
pulmonary edema. 
 
Colloid oncotic pressure 
 
 Pregnancy induced hypertension Normal 
Antepartum 18 mm 22mm 
Postpartum 14mm 17mm 
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Hematological changes 
 
Hypercoagulopathy 
Activation of fibrinolytic system 
Platelet activation 
 
Renal function 
 
Glomerular filtration rate decreased by 25% 
Proteinuria 
Hypeuricemia>5.5mg% associated with perinatal morbidity and mortality 
Oliguria<400ml/24hours 
 
Endocrine system 
 
Renin angiotensin aldosterone system increased in normal pregnancy while it is 
suppressed in pregnancy induced hypertension 
 
Respiratory system 
 
Pharyngo laryngeal edema 
Pulmonary edema-3%of cases 
30%-antenatal 
70%-postnatal due increased fluid administration before delivery. 
 
Hepatic function 
 
Increased Alanine transaminase 
Epigastric/subcostal pain 
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Neurolgical changes 
 
Severe headache, visual disturbances, central nervous system 
hyperexcitability, hyperreflexia, seizures. 
 
Seizures can happen even if blood pressure<140/90(20%cases) 
 
Uteroplacental perfusion 
 
Decreased 
 
 
 
HELLP syndrome 
 
Severe form of Pregnancy induced hypertension 
 
1.Hemolysis-Abnormal peripheral smear & serum bilirubin>1.2mgm 
2.Platelet count <100,000/l 
3.AST>70IU/l&LDH>600U/l 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 Management of severe PIH 
 
Management of severe pregnancy induced hypertension requires 
multidisciplinary approach. 
 
Prophylaxis 
 
Aspirin 60 –100mgm/day.  Not well established 
Oral calcium 2gm/day.    Not well established 
 
Definitive treatment consists of termination of pregnancy along with prevention 
of seizures and control of blood pressure. 
 
Obstetric management 
 
Regardless of gestational age immediate delivery is advocated in 
 
1.Persistant severe hypertension for24-48hrs 
2.Progressive thrombocyopenia (<100000) 
3.Progressive renal dysfunction (urine output<0.5ml/kg/mt, serum creatinine 
1mg%above baseline) 
4.Premonitary signs of eclampsia 
5.Fetal jeopardy 
6.Pulmonary edema 
7.Elevated liver enzymes ALT/AST>2times normal with abdominal pain 
8.A.F index<2 
14 
 
Drug therapy 
 
Magnesium sulphate for seizure prophylaxis. 
 
Antihypertensives-to bring diastolic blood pressure between 105-125 mmHg 
and Mean arterial blood pressure 90-105 mmHg. 
 
The drugs used in the control of blood pressure are oral antihypertensives 
Alphamethyldopa, Nifedipine, Labetalol, intravenous agents like Hydralazine, 
Labetalol, Nitroglycerin etc. 
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PHARMACOLOGY OF LABETALOL 
 
Antihypertensive agent  
Belongs to class Betablockers 
Chemistry 
 
2-hydroxy-5-(1-hydroxy-2-(4-phenylbutan-2-ylamino0-ethyl)-benzamide 
Formula C19H24N2O3 
Molecular mass 328.406g/mol 
 
 
Mechanism of action 
 
Competitive antagonist of alpha1, beta1 Adrenergic receptors & agonist of beta2 
Adrenergic receptors. 
Clinical formulation contains 4 diastereoisomers with net beta to alpha blocking 
potency3: 1 for oral Labetalol and 7:1 for intravenous Labetalol. 
Adrenergic receptors have been divided into alpha and beta receptors and further 
subdivided into alpha1, alpha2 and beta1, beta2, beta3 receptors. 
Alpha1 receptors are present mainly in smooth muscle mediating vasoconstriction. 
Alpha2 receptors are present in presynaptic membrane. 
Beta1 receptors are present mainly in heart. 
Beta2 receptors found in smooth muscle cells mediating relaxation. 
After Adrenergic receptor stimulation, the extracellular signal is transformed into 
an intracellular signal by a process known as signal transduction in which 
alpha1and beta receptors are coupled to G proteins. G proteins are found on the  
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inner surface of the cell membrane. G proteins when activated can modulate the 
synthesis or availability of intracellular second messangers. 
 
Pharmacokinetics 
 
Oral absorption-90% 
Bioavailability-20-40%(extensive first pass metabolism in liver) 
Protein binding-50% 
Metabolism-oxidative biotransformation and glucuronidation in liver 
Elimination half-life is 5-8hours 
 
Phamacodynamics 
 
Clinical formulation contains 4 diastereoisomers with net beta to alpha blocking 
potency3;1 for oral Labetalol and 7:1 for intravenous Labetalol. 
Reduces systemic blood pressure 
Reduces heart rate 
Cardiac output remains unchanged. 
Peak blood pressure lowering effect is in 5-10 minutes. 
 
Adverse effects 
 
Orthostatic hypotension 
Bronchospasm in susceptible individuals 
Congestive heart failure 
Heart block 
Bradycardia 
Fatigue 
Drowsiness 
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Uses 
 
Systemic hypertension 
Hypertensive crisis 
Pregnancy induced hypertension 
Anginapectoris 
 
Contraindications 
 
Congestive heart failure 
Heartblock 
Hypotension 
Peripheral vascular disease 
 
Formulation 
 
Oral tablets-50,100,200,300mgm (max2.4gm/day) 
Intravenous injection-5mg/ml(max300/day) 
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PHARMACOLOGY OF ALPHAMETHYLDOPA 
 
A centrally acting antihypertensive 
CHEMISTRY 
 
2-amino-3-(3,4-dihydroxyphenyl)-2metyl-propanoicacid 
An analogue of 3,4-dihydroxy-L-phenyl alanine (DOPA) 
Formula C10H13NO4 
Molecular mass 211.215g/mol 
 
 
 
Mechanism of action 
 
Alphamethyldopa gets converted into Alphamethyldopamine then to Alpha 
methylnorepinephrine. Alphamethylnorepineprine replaces Norepinephrine in 
neurosecretory vesicles in brainstem. It acts as an Alpha2 Adrenergic receptor 
agonist, attenuates the output of vasoconstrictor Adrenergic signals to peripheral 
sympathetic nervous system. 
Pharmacokinetics 
 
When administered orally it is absorbed by active amino acid transporter with 50% 
bioavailability. 
Peak plasma concentration-2-3hours 
Metabolized in liver (50-70 %sulfate conjugates &other metabolites) 
Elimination half-life 2 hours 
25% of parent drug and Metabolites excreted in urine. 
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Pharmacodynamics 
 
Fall in systemic vascular resistance without much change in heart rate, cardiac 
output, and postural hypotension. 
Reverses left ventricular hypertrophy in 12 weeks without apparent relationship to 
degree of change in arterial pressure. 
Maximum effect seen 6-8 hours after oral dose. 
Duration of action of single dose-24hours (so single/twice daily dose) 
 
Adverse effects 
 
Sedation 
Dry mouth 
Decrease in libido 
Parkinsonian signs  
Hyperprolactinemia-galactorrhoea 
Bradycardia 
Elevated liver enzymes 
Hepatotoxicity 
Hemolytic anemia 
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CALCIUM ION ENTRY AND EXIT FROM A VASCULAR SMOOTH 
MUSCLE 
 
 
 
 
PHARMACOLOGY OF NIFEDIPINE 
 
Chemistry 
 
Antihypertensive belonging to class of Calcium channel blockers 
1,4,-dihydropyridine subclass 
Dimethyl2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
 
 
C17H18N2O6 
Molecular mass 346.335g/mol 
 
Mechanism of action 
 
Voltage gated Calcium channels are present in cell membrane of all skeletal 
muscle, vascular smooth muscle, cardiac cell, mesenteric muscle, neurons. 
Of the two types (L&T) of voltage gated Calcium ion channels present in the 
cardiovascular system, L type is the main channel for slow and sustained Calcium 
ion entry into vascular smooth muscle cells. 
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 MECHANISM OF ACTION OF CALCIUM CHANNEL BLOCKER 
 
 
 
 
 
 L type Calcium channel has 5 subunits-alpha1, alpha2, beta, gamma, delta, 
theta. Alpha1 subunit forms the central part of Calcium ion channel and provides 
the main pathway for Calcium ion entry into cell. 
Direct activation of vascular smooth muscle cell voltage gated Calcium ion 
channel by nervous stimulus initiates an action potential, calcium ion influx and 
myofilament activation (excitation-contraction coupling).the intracellular Calcium 
combines with Calmodulin, the calcium binding protein to form the Calcium-
Calmodulin complex.This complex activates Myosin and causes the formation of 
cross bridges with Actin. These cross bridges begins the process of muscular 
contraction. 
 
Pharmacokinetics 
 
Oral absorption-90% 
Bioavailability-60% 
Protein binding –90% 
Metabolism by liver is complete. 
Metabolites inactive and excreted by urine 
Elimination half life-2-5hours 
 
Pharmacodynamics 
 
Decreases systolic blood pressure, diastolic blood pressure, 
Heart rate may increase (reflux tachycardia)  
Myocardial depression (mild) 
Coronary artery dilation 
Peripheral artery dilation. 
22 
 
 
Adverse effects 
 
Headache, flushing 
Excessive myocardial depression in preexisting left ventricular 
dysfunction/concomitant Betablocker therapy 
 
 
Therapeutic uses 
 
Hypertension 
Angina pectoris 
Raynauds phenomenon 
Tocolytic 
Anal fissures 
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  PHARMACOLOGY OF NITROGLYCERIN 
 
Antihypertensive. 
Chemistry: 
 
Chemical name    1,3 - dinitrooxypropan-2-yl-nitrate  
Formula  C3H5N309  
Molecular weight  : 227.1 
Pharmacokinetics 
 
Volume of distribution : 3.3.1 /kg 
Plasma protein binding : 60% 
Oral Absorption : Incomplete 
Presystemic metabolism : Extensive 
Plasma half life range : 1-3 min 
 
Lipophilic, which allows rapid and complete absorption from skin and mucosa. 
Metabolism: 
 
Rapid liver degradation hydrolysis by nitrate reductase which result in low 
bioavailability. Thus bioavailability is much higher when drug is given 
transmucosally by sublingual, translingual (spray), transmucosal (buccal) or 
transdermal routes or intranasal route. 
It is excreted in bile and urine. 
 
Formulations 
 
Tablets  : 0.15 - 0.6mg 
Spray  :  0.4mg/metered dose Spray 
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Surfaced release capsule : 2.5 - 9mg 
Buccal (Transmucosal)  : 1mg 
Ointment  :  15 mg/inch 
Transdermal disc  : 1 disc (2.5-15mg) 
Intravenous  : 1-2. microgm/kg 
PHARMACODYNAMICS 
Mechanism of action 
 
The nitrates enter the smooth muscle cell and are converted to reactive (NO) 
or S-nitrosothiol which stimulates guanylate cyclase metabolism to produce 
cGMP. A cGMP dependent protein kinase is stimulated with resultant protein 
phosphyorylation in smooth muscle. This leads to a dephosphorylation of the 
mysoin light chain and smooth muscle relaxation. 
CARDIO VASCULAR SYSTEM 
 
Nitroglycerine induced vasodilation occurs throughout the vascular tree with a 
dose related specificity.Low doses predominantly produce venodilation. 
At higher doses nitroglycerine dilates smaller arterioles and resistance vessels, 
which reduces after load and blood pressure. 
Venodilation produces pre-load reduction, leading to a reduction in myocardial 
oxygen demand due to lessened ventricular wall stress via reduced chamber size 
and end - diastolic pressure. 
Decreases right atrial, pulmonary artery and pulmonary artery wedge pressure. 
Renal arteries, cerebral arteries and cutaneous vessels also dilate. 
The indirect effects of nitroglycerine consists of reflexes evoked by baroreceptors 
and harmonal mechanism responding to decrease in arterial pressure. 
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The primary mechanism of this reflex is sympathetic discharge consistently results 
in tachycardia and increased cardiac contractility. 
SMOOTH MUSCLE ORGANS 
 
Relaxation of smooth muscle of the bronchi, GIT, GUT. 
 
Adverse effects 
 
Vasodilation 
Hypotension 
Reflex Tachycardia 
Throbbing head ache 
Drug rash in transdermal patches 
Hypoxaemia via worsening ventilation perfusion mismatch through pulmonary 
vasodilation. 
Methemoglobinemia. 
 
THERAPEUTIC USE 
Indications 
 
1.  Relief of angina 
2.  Acute myocardial infarction 
3.  Acute pulmonary edema 
4.  Hypertension 
5.  Oesophageal spasm. 
26 
Contra indications 
 
1.  Low cardiac output secondary to hypovolemia 
2.  Obstructive cardiomyopathy 
3.  Raised intracranial pressure 
4.  Cardiac Tamponade 
Relative contra indication 
 
1.  Arterial hypoxaemia & corpulmonale 
2.  Mitral valve prolapse 
3.  Glaucoma 
 
DRUG INTERACTIONS: 
 
Hypotension occurs with  
1. Calcium channel blockers 
2. Antihypertensive agents.  
3. Phenothiazines 
4. Tricyclic antidepressants 
5. Alcohol 
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 PHARMACOLOGY OF MAGNESIUM SULPHATE 
 
 
Anticonvulsant/Antiarrythmic/Tocolytic 
 
Chemistry 
 
Formula- MgSO4.7H2O 
Molecular mass 120.415 
 
Mechanism of action 
 
Blocks neuronal calcium influx through the glutamate channel. 
N-methyl-D-aspartate(NMDA)receptors in hippocampal region are blocked. 
 
Pharmacodynamics 
 
Anticonvulsant activity in severe Pregnancy induced hypertensive patients. 
Reduces systemic vascular resistance and mean arterial pressure and increases 
cardiac index, though cardiovascular effects last for about 15 minutes despite 
continued infusion. 
 
Dose dependant inhibition of uterine muscular contractility(a minimum  
serum magnesium level of 8 to 10 meq/l is required).Magnesium sulphate did not 
significantly alter oxytocin stimulation of labour. 
 
Neonatal depression can occur in severe hypermagnesemia. 
 
Orally administered magnesium sulphate has laxative effect.  
 
Broncho dilator. 
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Pharmacokinetics 
 
Administered intra muscularly /intravenously. 
Excreted by the kidneys. 
 
Adverse effects 
 
Dose dependant 
 
Normal serum level           1.5-2.0meq/l 
Therapeautic level 4.0-8.0meq/l 
Prolonged PQ interval, QRS widening 5.0-10 meq/l 
Deep tendon reflex absent 10 meq/l 
Sinoatrial/atrioventricular  block, Respiratory paralysis 15meq/l 
Cardiac arrest 25 meq/l 
                      
Adverse effects are monitored by respiration, deep tendon reflexes, urinary 
output and serum magnesium levels. Inj Calcium gluconate 10 ml slow iv is used 
to treat magnesium toxicity. 
 
Therapeutic uses 
 
Anticonvulsant 
Bronchodilator 
Antiarrythmic (torsades des pointes) 
Tocolysis 
Hypomagnesemia 
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REVIEW OF LITERATURE 
 
Ramanathan J et al in their study of anesthetic modification of 
hemodynamic and neuroendocrine stress response to caesarean delivery in women 
severe preeclampsia observed that after pretreatment with Labetolol or 
Nitroglycerine mean arterial pressure decreased from 131.5 +/- 4.9 mmHg to 
112.2+/- 3.5 mmHg (21). 
Vigil – De gracia p et al in their   randomized clinical trial (severe 
hypertension in pregnancy: Hydralazine or Labetalol) observed that Labetalol 
fulfilled the criteria required for an antihypertensive to treat severe hypertension in 
pregnancy (26). 
        
Belfort MA et al in their study observed that Labetolol is an ideal agent for 
blood pressure control in severely hypertensive pregnant women (2). 
 
Gilson GJ et al in their investigation concluded that incidence of pulmonary 
edema in patients with severe preeclampsia who are treated with Labetalol appears 
to be a result of an increase in third space fluid accumulation as a manifestation of 
the severity of their disease, not a direct effect of the drug on cardiac  
performance (11). 
 
Schobel HP et al in their data indicated that the increases in peripheral 
vascular resistance and blood pressure that characterize this disorder are mediated, 
at least in part, by a substantial increase in sympathetic vasoconstrictor  
activity. (25) 
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Wallace DH et al in their study concluded that general as well as regional 
anesthetic methods are equally acceptable for cesarean delivery in pregnancies 
complicated by severe preeclampsia if steps are taken to ensure a careful approach 
to either method.(27) 
 
Kwawukume EY et al in their study concluded that Nifedipine and 
Hydralazine could both be used effectively to control blood pressure in severe 
preeclampsia. While Hydralazine is administered intravenously and needs strict 
monitoring, Nifedipine is more effective, is easy to administer orally, less 
demanding on hospital staff, convenient and more predictable. (14) 
 
El-Qarmalawi AM, et al in their study concluded that Labetalol is better 
tolerated than Alphamethyldopa, gives more efficient control of blood pressure and 
may have a ripening effect on the uterine cervix. (8). 
 
Mahmoud TZ, et al in their study observed that Labetalol allows safe 
prolongation of pregnancies complicated by Pregnancy induced hypertension 
(PIH). (17) 
Kumar N et al in their study observed that there was a decrease in mean 
arterial blood pressure (MAP) after pretreatment with Nifedipine. The increase in 
mean arterial pressure (MAP) during laryngoscopy and intubation was higher in 
the control group compared with Nifedipine pretreatment group. During 
laryngoscopy and intubation, Mean arterial pressure decreased by 3 mmHg in the 
Nifedipine pretreatment group, while there was an increase of 14 mmHg in the 
control group. Heart rate increased in both the groups during the laryngoscopy and 
tracheal intubation but the increase was higher in the Nifedipine group than in the  
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control group. Neonatal Apgar scores in both the groups were comparable. These 
results suggest that sublingual Nifedipine is effective in attenuating the 
hypertensive response to laryngoscopy and intubation but not the tachycardiac 
response in parturients with pregnancy induced hypertension (PIH). (13) 
 
Olsen KS et al in their study observed hemodynamic collapse following 
Labetalol administration in preeclampsia. On the 3rd day after a cesarean section, 
because of pre-eclampsia, blood pressure was still high, oral Labetalol 100 mg 
with an 8-hour interval was given, followed by 50 mg i.v. administered over 10 
min, twice with a 5-hour interval. The last injection was immediately followed by 
an atrio-ventricular tachycardia with massive decrease in blood pressure. (20) 
 
Olsen KS et al in their study observed fetal death following Labetalol 
administration in pre-eclampsia.  
Labetalol (Trandate) 50 mg i.v was administered to a pre-eclamptic  
primigravida with an asphytic fetus prior to cesarean section, in order to reduce the 
risk of excessive increase in blood pressure during induction of anesthesia. Blood 
pressure fell rapidly from 170/110 to 115/85 mmHg. A dead infant was born. Oral 
Labetalol is arguably a suitable remedy for pre-eclampsia, but if i.v administration 
is necessary, an initial dose of 5-10 mg is recommended. (19) 
 
Chung KS et al in their study concluded that an intermediate dose of 
Labetalol blunted the heart rate response to laryngoscopy and intubation during 
rapid-sequence induction in healthy patients but had a minimal effect on blood 
pressure. (5) 
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Montan, Sven; et al in their study on effects of Alphamethyldopa on 
uteroplacental and fetal hemodynamics in pregnancy-induced hypertension 
observed that Alphamethyldopa in the last trimester in women with pregnancy-
induced hypertension reduced maternal blood pressure and heart rate but had no 
adverse effects on uteroplacental and fetal hemodynamics. (18) 
 
Lee SC et al in their study on effects of Labetalol and Nitroglycerin during 
induction of anesthesia and endotracheal intubation in hypertensive patients 
concluded that both drugs blunted the hypertensive response to endotracheal 
intubation, intravenous Labetalol seemed safer and more effective than 
Nitroglycerin to attenuate the hypertensive response to laryngoscopy and 
intubation in hypertensive patients. (15)  
   
Leslie JB, et al in their study on attenuation of the hemodynamic responses 
to endotracheal intubation with preinduction intravenous Labetalol showed that IV 
Labetalol at doses up to 0.75 mg/kg offers an effective pharmacologic means of 
attenuating preoperative hemodynamic responses to endotracheal intubation. (16). 
 
Connell H,et al in their study on  general anaesthesia in mothers with severe 
pre-eclampsia/eclampsia observed that the average increase in systolic arterial 
pressure  was 56.4 mm Hg following laryngoscopy and tracheal intubation. (6) 
Scardo,james.A et al in their randomized, double-blind, hemodynamic 
evaluation of Nifedipine and Labetalol in preeclamptic hypertensive emergencies 
concluded that Nifedipine increases cardiac index, whereas Labetalol may not do 
so. (27) 
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MATERIALS AND METHODS 
 
After obtaining the necessary institutional and ethical committee clearance 
following study was conducted in the Institute of obstetrics and gynecology, 
(IOG), Madras Medical college &Research Institute, Chennai .All antenatal 
mothers were screened for severe pregnancy induced hypertension (PIH) in the 
casualty department and 40 patients with severe PIH were selected. Informed 
consent was obtained from them and randomly divided into 2 groups namely group 
A and group L of 20 each. 
Inclusion criteria:(any one of the following) 
 
1. Systolic blood pressure> 160mmHg 
2. Diastolic blood pressure>110mmHg 
3. Proteinuria (dipsticks)>+3or+4 
4. History of oliguria or urine output < 500ml in 24 hours 
5. Presenting with imminent features– blurring of vision, epigastric pain, 
hyperreflexia, HELLP 
 
Exclusion criteria:  
 
1. Secondary hypertension 
2. Cardiac arrhythmia 
3. Bronchial asthma 
4. Diabetes mellitus 
5. Complications due to severe Pregnancy induced hypertension like 
intracerebral hemorrhage, acute left ventricular failure, coagulopathy, 
bleeding disorders                                     
6. Patients already on oral antihypertensives are not included in-group L. 
34 
Selected patients were examined and the nature of disease and its treatment 
explained to them. They were made to lie down in supine position with a 15 – 25 
degree lateral tilt by placing a wedge below the right hip to avoid supine 
hypotension syndrome/aortocaval compression.  All patients were maintained on 
nil per status since admission. Baseline parameters like weight, height, blood 
pressure, heart rate, respiratory rate, temperature, spo2, Jugular venous pulse, and 
fetal heart rate were recorded. A 16G intravenous line was started in the dorsum of 
left hand and ringer lactate was administered at 85 ml per hour. Urinary bladder 
was catheterized and urine output monitored. Blood sample was collected and sent 
for following investigations:  Blood grouping/typing, Hb, PCV, urea, creatinine, 
electrolytes, sugar, uric acid, fibrinogen, platelet count, bleeding time, clotting 
time.  
                             
Group A patients were administered two tablets of Alphamethyldopa 250 mgms 
and one tablet of Nifedipine 10mgm each with a sip of water in the casualty itself. 
They were shifted to intensive care unit (ICU) where they were monitored for 
control of Blood Pressure/progress of pregnancy/seizures. If 3 hours after starting 
oral antihypertensive combination either the mean arterial pressure (MAP) / 
diastolic blood pressure (DBP) is found to be more than 125 mmHg/ 105 mmHg 
then injection Nitroglycerin infusion is administered at 5 microgram/kg/min as a 
rescue drug. 
Group L patients were not administered anything in casualty department. They 
were shifted to intensive care unit (ICU) where they were monitored for control of 
Blood pressure/progress of pregnancy/seizures. In the ICU injection Labetalol 20 
mgms intravenous was administered slowly and repeated every 10 minutes if 
necessary. 
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The aim in both groups of patients is to achieve a target blood pressure of 
mean arterial pressure 105 – 125 mmHg and diastolic blood pressure 90 – 105 
mmHg. 
Both group of patients were administered 4 gms of magnesium sulphate 
intravenously over 30 minutes in 100 ml of Normal saline followed by 
administration of 1 gm/hr magnesium sulphate I.V. for the next 24 hrs. The 
patients were monitored for evidence of magnesium toxicity like absence of tendon 
reflexes, diminished respiration and urine output. If it is found the administration 
of magnesium sulphate is stopped and calcium gluconate 1 gm I.V. is administered 
slowly with ECG monitoring. 
 
The following parameters were recorded every 5 minutes during the study. 
 
1. Systolic blood pressure (SBP) 
2. Diastolic blood pressure (DBP) 
3. Mean arterial pressure (MAP) 
4. Heart rate 
5. Fetal heart rate 
6. Spo2 – room air 
7. Urine output (Hourly) 
 
The administration of either Nitroglycerin or Labetalol is tapered / stopped 
respectively if 
1. Diastolic blood pressure < or = 105 mmHg and mean arterial pressure < or 
= 125 mmHg 
2. Heart rate < 60/min 
3. Labetalol > 2mgm/kg body weight 
36 
4. Fetal heart rate < 120/min or > 160/min 
If any patient developed diastolic blood pressure < 90 mmHg or mean arterial 
pressure < 105 mmHg even after stopping all antihypertensives, patient is 
administered humidified 100% oxygen by face mask, adequately ventilated and 
fluid infused rapidly until diastolic blood pressure more than 90 mmHg / mean 
arterial pressure > 105 mmHg with caution to avoid pulmonary edema.  
 
If any patient developed heart rate < 60 /min and features of symptomatic 
bradycardia (shortness of breath, light headedness, angina, ischemic changes, cool 
peripheries, diastolic blood pressure / mean arterial pressure < 90 / 105 mmHg), 
injection Labetalol is stopped, patient is administered humidified 100%oxygen by 
face mask, adequately ventilated and fluid infused rapidly until diastolic blood 
pressure more than 90 mmHg / mean arterial pressure > 105 mmHg, injection 
atropine 0.3 – 0.5 bolus repeated if necessary at 5 min intervals ( maximum 3 
mgm) with caution to avoid pulmonary edema. 
In our study pregnancy was terminated for obstetric reasons in all patients of 
both groups. After premedication with 0.2 mgm Glycopyrrolate intramuscular, 10 
mgm injection Metaclopromide intramuscular and injection Ranitidine 50 mgm 
intravenous emergency termination of pregnancy is accomplished by  
 
1. Induction of labour and normal vaginal delivery (only one patient in group L 
who failed to achieve target blood pressure) 
2.  Emergency LSCS under general anesthesia (4 patients in group A who failed 
to achieve target blood pressure) 
3.  Emergency lower segment cesarean section (LSCS) under regional 
anesthesia (all patient in both groups who achieved target blood pressure) 
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Patients were explained and informed consent was obtained for LSCS. In the 
operation theatre anesthesia machine was checked, emergency medicines, suction 
apparatus, laryngoscopes, appropriate sized endotracheal tubes (ETT), laryngeal 
mask airway, Guedal’s airways were kept ready. Patients were connected to 
monitors including Non invasive blood pressure, Spo2, ECG, respiration, 
temperature. All patients were made to lie down in supine position with a 15 – 25 
degree lateral tilt by placing a wedge below the right hip to avoid supine 
hypotension syndrome/aortocaval compression. 
 
Subarachnoid block was chosen as the regional technique. With aseptic 
precautions patients were administered 2.2 ml of 0.5% Bupivacaine hydrochloride 
heavy (spinal preparation) in the L3/4 space in the lateral position. All patients 
were made to lie down in supine position with a 15 – 25 degree lateral tilt by 
placing a wedge below the right hip to avoid supine hypotension 
syndrome/aortocaval compression. After ascertaining sensory level of T6 
emergency LSCS was allowed to proceed. Any episode of hypotension was 
managed with administration of humidified 100% oxygen, adequate ventilation, 
rapid crystalloid infusion, injection ephedrine 6 mg intravenous boluses and 
injection atropine 0.3 to 0.5 mg boluses if necessary. After the delivery of baby and 
cord is clamped injection Oxytocin is administered at 20 to 40 IU / hr. Neonatal 
outcomes were recorded.  
 
For emergency LSCS under general anesthesia patients were made to lie down 
in supine position with a 15 – 25 degree lateral tilt by placing a wedge below the 
right hip to avoid supine hypotension syndrome/aortocaval compression. Patients 
are draped, preoxygenated with 100% o2 for 5 min. Then injection Thiopentone  
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sodium 5 mg/kg, 2.5% solution was administered over 5 – 15 seconds immediately 
followed by injection Suxamethonium hydrochloride 1.5 mg/kg body weight rapid 
push. 20 seconds later cricoid pressure was applied. 45 seconds after the 
administration of Suxamethonium hydrochloride laryngoscopy is done, patient is 
intubated with 6.0/6.5/7.0 endotracheal tube. After confirming position of ETT by 
physical methods ETT cuff is inflated and cricoid pressure released. ETT is 
secured with tapes, patient is ventilated with N2O/O2 5:5 until baby delivery (4:2 
after baby delivery). LSCS is allowed to proceed, injection Oxytocin 20 to 40 
IU/hr and injection Fentanyl citrate 100 micrograms intravenous are administered 
after baby delivery and cord is clamped . Nondepolarising muscle relaxants 
injection Vecuronium bromide is used if necessary. After the surgery is over the 
patient is administered injection Neostigmine methylsulphate 50 microgram/kg and 
Glycopyrrolate 10 microgram/kg to antagonise any residual neuromuscular 
blockade. After complete recovery of the patient extubation is done. The patient is 
shifted back to ICU for postoperative care. Neonatal outcomes were recorded.   
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RESULTS AND OBSERVATION 
 
The results were evaluated using students t test comparing between the 
groups and within the group. 
 
                 TABLE NO-I AGE DISTRIBUTION (YEARS) 
 
 GROUP A(n=20) GROUP L(n=20) p value 
MEAN 25.2  25 
S.D 3.33 2.87 
MEDIAN 24.5 24.5 
RANGE 21-35 21-37       
 
0.84(not 
significant) 
 
Table no-1 shows the age distribution range and mean ages observed in both 
groups.In Group A the mean age is 25.2 years .In Group L the mean age is 25 
years. Both Groups are comparable with p value (0.84) not significant. 
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TABLE NO-II GESTATATIONAL AGE (WEEKS) 
  
 GROUPA (n=20) GROUPL (n=20) p value 
MEAN 32.8 33.5 
S.D 1.92 2.11 
MEDIAN 32 33.5 
RANGE 30-37 30-37 
 
0.28(not 
significant) 
 
 
Table no-2 shows the distribution range and mean gestational ages observed 
in both groups. In Group A the mean gestational age is 32.8 weeks. In Group L the 
mean gestational age is 33.5 weeks. Both Groups are comparable with p value 
(0.28) not significant. 
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TABLE NO-III WEIGHT DISTRIBUTION (IN KGS) 
 
 
 GROUPA (n=20) GROUP L (n=20) p value 
MEAN 63.1 64.8 
S.D 3.91 5.44 
MEDIAN 62.5 63.5 
RANGE 56-72 56-80 
 
0.25(not 
significant) 
 
 
Table no-3 shows the distribution, range and mean weight observed in both 
groups. In Group A the mean weight is 63.1 kgs. In Group L the mean weight is 
64.8 kgs. Both Groups are comparable with p value (0.25) not significant. 
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TABLE NO-IV HEIGHT DISTRIBUTION (IN CENTIMETERS) 
 
 
 GROUPA (n=20) GROUPL (n=20) p value 
MEAN 145.8 149.4 
S.D 5.77 6.55 
MEDIAN 143.5 148.5 
RANGE 140-159 140-164 
 
0.07(not 
significant) 
 
 
Table no-4 shows the distribution, range and mean height observed in both 
groups In Group A the mean height is 145.8cms. In Group L the mean height is 
149.4cms. Both Groups are comparable with p value (0.07) not significant. 
 
 
TABLE NO V-DEMOGRAPHIC PROFILE 
 
 
MEAN VALUES GROUP A (n=20) GROUP L (n=20) 
AGE (years) 25.2 25 
WEIGHT (kgms) 63.1 64.8 
HEIGHT (cms) 143.5 148.5 
 
 
Table no 5 shows the patient characteristics, age height and weight observed 
in both groups.  
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TABLE NO-VI FAILURE RATE TO ACHIEVE BLOOD PRESSURE 
CONTROL 
 
 GROUPA(n=20) GROUPL (n=20) p value 
FAILURE 20% 5% 0.34(not 
significant) 
 
 
Table no-6 shows the failure rate to achieve blood pressure control in both 
groups. In Group A out of 20 patients 4 patients (20%) failed to achieve blood 
pressure control despite using injection nitroglycerin as rescue drug. In Group L 
patients only one patient (5%) failed to achieve blood pressure control .The failure 
rate between the 2 groups is not statistically significant with p value (0.34)   
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TABLE NO –VII TIME TO ACHIEVE TARGET BLOOD PRESSURE (in 
minutes) 
 
TIME GROUPA(n=16) GROUPL (n=19) p value 
MEAN 185.9 46.8 
S.D 20.75 11.57 
 
<0.001(significant)
 
Table no-7 shows the mean, standard deviation of the time taken to achieve 
target blood pressure in both groups. In Group A patients (n=16) the mean time 
taken to achieve target blood pressure is 185.9 minutes. In Group L patients (n=19) 
the mean time taken to achieve target blood pressure is 46.8 minutes .The time 
difference to achieve target blood pressure between the 2 groups is statistically 
significant  (p value<0.001) 
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TABLE NO-8 CHANGES –SYSTOLIC BLOOD PRESSURE (mm Hg) 
 
 
 GROUP A(n=20) GROUP L(n=20) p value 
BEFORE 
TREATMENT 
   
MEAN 178.1 184.7 0.22(not significant) 
S.D 14.34 19.16  
  GROUPA(n=16) GROUPL(n=19) P value 
AFTER 
TREATMENT 
   
MEAN 151.8 146.2 0.002(significant) 
S.D 5.34 4.50  
 
 
Table-no –8 shows the changes in systolic blood pressure in the 2 groups. 
In Group A the mean systolic blood pressure before treatment is 178.1 mmHg. 
In Group L the mean systolic blood pressure before treatment is 184.7 mmHg. 
Both groups are comparable with p value (0.22) not significant. 
In Group A the mean systolic blood pressure after treatment is 151.8 mmHg. 
In Group L the mean systolic blood pressure after treatment is 146.2 mmHg. 
The p value 0.002 suggests the statistical significance that in Group L patients 
(n=19) achieved better and lower mean systolic blood pressure after treatment than 
Group A patients (n=16). 
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TABLE NO-9   CHANGES-DIASTOLIC BLOOD PRESSURE (mm Hg) 
 
 
 GROUPA(n=20) GROUPL(n=20) p value 
BEFORE 
TREATMENT 
   
MEAN 118.7 122.7 0.234(not significant) 
S.D 12.16 8.43  
 GROUPA(n=16) GROUPL(n=19) P value 
AFTER 
TREATMENT 
   
MEAN 100.4 100.6 0.91(not significant) 
S.D 4.15 3.42  
 
 
Table no-9 shows the changes in diastolic blood pressure in the 2 groups. 
In Group A the mean diastolic blood pressure before treatment is 118.7 mmHg. 
In Group L the mean diastolic blood pressure before treatment is 122.7 mmHg. 
Both groups are comparable with p value (0.234) not significant. 
In Group A the mean diastolic blood pressure after treatment is 100.4 mmHg. 
In Group L the mean diastolic blood pressure after treatment is 100.6 mmHg. 
There is no statistical significance between the 2 Groups with p value 0.91.   
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TABLE NO-10   CHANGES-MEAN ARTERIAL BLOOD PRESSURE  
(mm Hg) 
 
 GROUPA(n=20) GROUPL(n=20) p value 
BEFORE 
TREATMENT 
   
MEAN 140.8 143.4 0.51(not 
significant) 
S.D 12.35 11.63  
 GROUPA(n=16) GROUPL(n=19) P value 
AFTER 
TREATMENT 
   
MEAN 118.1 115.8 (0.09)(Not 
significant) 
S.D 4.57 3.01  
 
Table no-10 shows the changes in mean arterial blood pressure in the 2 groups 
In Group A patients (n=20) the average mean   arterial blood pressure before 
treatment is 140.8 mmHg. 
In Group L patients (n=20) the average mean blood pressure before treatment is 
143.4 mmHg. 
Both groups are comparable with p value (0.51) not significant. 
In Group A patients (n=16) the average Mean blood pressure after treatment 
is118.1 mmHg. 
In Group L patients (n=19) the average Mean blood pressure after treatment is 
115.8 mmHg. 
There is no statistical significance between the 2 Groups with p value 0.09.   
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TABLE NO-11   CHANGES-MATERNAL HEART RATE (/min) 
 
 GROUP (n=16) GROUP (n=19) p value 
BEFORE 
TREATMENT 
   
MEAN 81.2 95.2 <0.001(significant)
S.D 7.29 6.68  
 GROUPA(n=16) GROUPL(n=19) P value 
AFTER 
TREATMENT 
   
MEAN 104.2 76.5 <0.001(significant)
S.D 11.48 7.89  
 
 
Table no-11 shows the changes in maternal heart rate in the 2 groups 
In Group A patients (n=16) the mean maternal heart rate before treatment is 
81.2/min. 
In Group L patients (n=19) the mean maternal heart rate before treatment is 
95.2/min. Both groups are not comparable with a   significant p value <0.001. 
In Group A patients (n=16) the mean maternal heart rate after treatment 
is104.2/min. In Group L patients (n=19) the mean maternal heart rate after 
treatment is 76.5/min. 
There is no statistical significance between the 2 Groups with p value <0.001.   
However in Group A patients (n=16) the difference between the mean maternal 
heart rate before and after treatment is a rise of+23/min (28.32%)showing a 
statistically significant p value<0.001.  This rise in maternal heart rate is due to the 
use of rescue drug injection nitroglycerin in group A patients. 
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In Group L patients (n=19) the difference between the mean maternal heart rate 
before and after treatment is a fall of-18.7/min (19.64%) showing a statistically 
significant p value <0.001. 
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TABLE NO-12   CHANGES-MATERNAL RESPIRATORY RATE (/min) 
 
 
 GROUPA(n=20) GROUPL(n=20) p value 
BEFORE 
TREATMENT 
   
MEAN 24.6 25.1 0.55(not 
significant) 
S.D 2-01 2.7  
 GROUP (n=16) GROUPL(n=19) P value 
AFTER 
TREATMENT 
   
MEAN 24.4 25.8 0.05(significant) 
S.D 1.09 2.71  
 
Table no-12 shows the changes in maternal respiratory rate in the 2 groups 
In Group A patients the mean maternal respiratory rate before treatment is 
24.6/min. In Group L patients the mean maternal respiratory rate before treatment 
is 25.1/min. Both groups are comparable with a p value 0.55 not statistically 
significant. 
In Group A patients the mean maternal respiratory rate after treatment is 24.4/min. 
In Group L patients the mean maternal respiratory rate after treatment is 25.8/min. 
There is statistical difference between the 2 groups with p value0.05. 
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TABLE NO-13   CHANGES-MATERNAL URINE OUTPUT (ml) 
 
 
 GROUPA(n=20) GROUPL(n=20) p value 
MEAN 175.0 137.5 0.07(not significant) 
S.D 59.60 65.60  
 
Table no-13 shows the changes in urine output the 2 groups In Group A patients 
the mean urine output is 175ml.In Group L patients the mean urine output is 
137.5ml.There is no statistical difference between the 2 groups with p value 0.07. 
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 TABLE NO-14   CHANGES-FETAL HEART RATE (/min) 
 
 GROUPA(n=20) GROUPL(n=20) p value 
BEFORE 
TREATMENT 
   
MEAN 135.2 137.8 0.15(not 
significant) 
S.D 4.87 6.15  
 GROUPA 
(n=16) 
GROUPL(n=19) P value 
AFTER 
TREATMENT 
   
MEAN 137.9 135.7 0.25(not 
significant) 
S.D 5.91 5.13  
 
Table no-14 shows the changes in fetal heart rate in the 2 groups. In Group A 
patients the mean fetal heart rate before treatment is 135.2/min. In Group L 
patients the mean fetal heart rate before treatment is 137.8/min. Both groups are 
comparable with a p value 0.15 not statistically significant. In Group A patients the 
mean fetal heart rate after treatment is 137.9/min. In Group L patients the mean 
fetal heart rate after treatment is 135.7/min. 
There is no statistical difference between the 2 groups with p value 0.25 
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TABLE NO -15 GROUP A 
 
 SBP (mmHg) 
DBP 
(mmHg)
MAP 
(mmHg)
Mat HR 
(/min) 
R.R 
(/min)
Fet 
HR(/min) U.O (ml)
TIME 
(min) 
BEFORE 
TREATMENT 
178.1+/-
14.34 
118.7+/-
12.16 
140.8+/-
12.35 
81.2+/-
7.29 
24.6+/-
2.01 
137.8+/-
6.15 
175.0+/-
59.60 
185.9+/-
20.75 
AFTER 
TREATMENT 
151.8+/-
5.34 
100.4+/-
4.15 
118.1+/-
4.57 
104.2+/-
11.48 
24.2+/-
1.09 
135.7+/-5.13   
 
 
 
TABLE NO- 16 GROUP L 
 
 
SBP 
(mmHg) 
DBP 
(mmHg) 
MAP 
(mmHg)
Mat 
HR(/min)
R.R 
(/min)
Fet 
HR(/min) U.O(ml)
TIME 
(min) 
BEFORE 
TREATMENT 
184.7+/-
19.16 
122.7+/-
8.43 
143.4+/-
11.63 
95.2+/-
6.68 
25.1+/-
2.7 
137.8+/-
6.15 
137.5+/-
65.60 
46.8+/-
11.57 
AFTER 
TREATMENT 
146.2+/-
4.5 
100.6+/-
3.42 
115.8+/-
3.01 
76.5+/-
7.89 
25.8+/-
2.71 
135.7+/-5.13   
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APGAR SCORES-1 MIN &5 MIN-DISTRIBUTION TABLE 
 
APGAR SCORE GROUPA (n=20) GROUPL (n=19) p value 
1 MIN 
           MEAN 
           S.D 
           MEDIAN 
           RANGE 
 
6.45 
0.61 
6 
6-8 
 
6.53 
0.61 
6 
6-8 
0.70(not 
significant) 
5 MIN 
           MEAN 
           S.D 
           MEDIAN 
           RANGE 
 
8.5 
0.51 
8.5 
8-9 
 
8.6 
0.50 
9 
8-9 
0.42(not 
significant) 
 
Table shows the distribution of Apgar scores of both group neonates at 1min and 
5min intervals. 
In group A neonates the mean Apgar at 1min is 6.45. 
In group L neonates the mean Apgar at 1 min is 6.53. 
Both groups are comparable with a p value of 0.70 
In group A neonates the mean Apgar at 5min is 8.5. 
In group L neonates the mean Apgar at 5 min is 8.6. 
Both groups are comparable with a p value of 0.42. 
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DISCUSSION 
 
In severe Pregnancy induced hypertension patients it is of vital importance to 
control high blood pressure preoperatively to reduce the incidence of maternal 
complications like pulmonary edema, intracerebral hemorrhage and renal failure. 
Fetal complications include intra uterine growth retardation (IUGR), perinatal 
mortality. 
Various drugs like methyldopa, ketanserin, hydralizine, labetalol, nifedipine have 
been used to control high blood pressure. 
 
Montan, Sven et al A in their prospective study before and after 1 week of 
methyldopa treatment observed that Maternal mean arterial blood pressure was 
reduced 9.7 mm Hg (95% confidence interval -13.8 to -5.6) from 
(114.5+/_6.1mmHg to 104.8+/_6.2 mmHg), and mean heart rate decreased 6.3 
beats/min (95% confidence interval -11.1 to -1.4)(from90.0+/_ to83.7+/-11.8). 
Fetal hemodynamic changes before and after treatment were not significant. Fetal 
and neonatal outcome was uneventful.(18)  
 
In our study group A patients were administered a combination of oral alpha 
methyldopa and nifedipine. Only 16 out of 20 patients achieved blood pressure 
control and 4 patients failed to achieve target blood pressure despite using 
intravenous nitro glycerin as rescue drug. Also out of the 16 patients who achieved 
blood pressure control 13 patients necessitated the use of rescue drug namely 
intravenous nitroglycerin. Only 3 patients achieved blood pressure control within 3 
hours after starting oral antihypertensive combination without use of rescue drug 
nitroglycerin. The maternal mean arterial blood pressure was reduced 22.7mmHg  
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from 140.8+/-12.35mmHg to 118.1+/-mmHg and but mean maternal heart rate 
increased 23/min from 81.2+/-7.29/min to 104.2+/-11.48/min due to nitroglycerin 
induced reflex tachycardia.   
 
In our study group L patients were administered intravenous labetalol. 19 out of 20 
patients achieved blood pressure control with one patient failing to do so. In that 
patient the dose was restricted to a maximum of 2mgm/kg, though a maximum of 
220 mgm per episode has been recommended. The maternal mean arterial blood 
pressure was reduced 27.4mmHg from 143.4+/- 11.63mmHg to 115.8+/-
3.01mmHg while the mean maternal heart rate was reduced 18.7/min from 95.2+/-
6.68/min to 76.5+/-7.89/min. Since Injection labetalol 20 mgm was administered 
intravenously and repeated every 10 minutes if necessary with careful monitoring, 
there was not any case of hypotension or hemodynamic collapse. One patient 
delivered a dead born baby .One of the known fetal complications of severe 
pregnancy induced hypertension is perinatal mortality due to uncontrolled 
hypertension. 
 
In our study Group L patients target blood pressure was achieved in a shorter time 
of 46.8+/-11.57min when compared to group A patients who took a longer time of 
185.9+/-20.75min. 
 
    In our study group L patients who received intravenous Labetalol for acute 
preoperative management of high blood pressure in severe Pregnancy Induced 
Hypertension (PIH) achieved more rapid blood pressure control with better heart 
rate control than Group A patients who received oral antihypertensives.  
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SUMMARY 
 
Comparative clinical study of acute preoperative management of high blood 
pressure in severe pregnancy induced hypertension patients using two methods: 
one by (group A) an oral combination of tablets Alphamethyldopa and Nifedepine 
and other by (group L) intravenous Labetalol was undertaken at the Institute of 
Obstetrics and Gynaecology,Madras medical college & research institute,  Chennai 
during the year 2006-2008. Summarizing the findings in the study: 
 
1.Oral antihypertensive combination of tablets Alphamethyldopa and Nifedepine 
achieved blood pressure control that often necessitated intravenous Nitroglycerin 
as rescue drug. 
2.Intravenous Labetalol achieves adequate and faster blood pressure control with 
better heart rate maintenance than the routinely used oral antihypertensive 
combination 
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CONCLUSION 
 
 
 In conclusion, intravenous Labetalol achieves adequete and faster blood 
pressure control with better heart rate maintenance than the routinely used oral 
antihypertensive combination of tablets Alphamethyldopa and Nifedipine in the 
control of blood pressure in preoperative severe pregnancy induced hypertension 
patients. 
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PROFORMA 
 
NAME :      AGE :  HOSP NO: 
  
 
 
 
OBSTETRICS H/O :      BOOKED /UNBOOKED 
 
HISTORY   C/O : 
 
H/o. PRESENTING ILLNESS : 
 
1. HEADACHE 
2. VISUAL DISTURBANCE 
3. RIGHT UPPER QUADRANT PAIN 
4. OLIGURIA 
5. FITS 
6. EDEMA 
7. ABNORMAL BLEEDING 
8. LAST VOIDING URINE 
9. MEMBRANES RUPTURED 
10. PAIN ABDOMEN 
11. NPO STATUS 
 
H/o. PAST ILLENSS   : 
 
1.  HYPERTENSION 
2.  DIABETESMELLITUS. 
3.  BRONCHIALASTHMA. 
4.  SEXUALLY TRANSMITTED DISEASES 
5.  RHEUMATIC HEART DISEASE 
6.  JAUNDICE 
7.  PREVIOUS SURGERY 
 
 
 
TREATMENT H/O. : 
  
 ANTIHYPERSIVE DRUGS 
  
 ALLERGY 
GENERAL EXAMINATION : 
- CONSCIOUS 
- ORIENTED 
- COMFORTABLE / PAIN / 
DYSPNOEIC 
- PALLOR 
- JAUNDICE 
- CLUBBING 
- CYANOSIS 
- EDEMA 
- SIGNIFICANT GENERALIZED 
LYMPHADENOPATHY 
- HYDRATION 
- HEIGHT 
WEIGHT 
- BMI 
- H.R. 
- B.P. 
- R.R. 
- TEMP. 
- JVP 
- SP02 
- BREAST & THYROID 
- SPINES 
- AIRWAY    
 MOUTH OPENING 
 MPC 
 THYROMENTAL 
DISTANCE 
 ANY DIFF. 
 
SYSTEMIC EXAM. 
1.  C.V.S. 
2. R.S. 
3. CNS 
4. ABDOMEN 
 
 
 
 
 
INVESTIGATIONS 
HB     URINE  
BLOOD GROUP   RH TYPE 
UREA    CREATININE   
ELECTROLYTES  URIC ACID 
SUGAR    FIBRINOGEN 
CLOTTING TIME  BLEEDING TIME 
 
 
 
 
 
 
 
 
 
 
 
EVENTS 
 
TIME 
SYST  
OLIC 
BP 
 
DIAST
BP 
MAP
Mm/ 
Hg 
 
HR/  
Min
 
 
Sp02
% 
 
RR/ 
Min 
 
 
UO 
Ml/ 
Hr 
FHR/min
ON ADMISSION          
ORAL/IV 
ANTIHYPERENSIVE 
START ED 
         
          
          
          
          
          
          
          
          
BLOOD PRESSURE 
TARGET 
ACHIEVED/FAILED 
         
TIME TAKEN (MIN)          
GROUP - A 
TIME  IN MINUTES AFTER STARTING TREATMENT 
SYSTOLIC BLOOD PRESSURE (mm Hg) DIASTOLIC BLOOD PRESS
                                         
 0 20 40 60 80 100 120 140 160 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 0 20 40 60 80 100 120 140 160 180 185 190 195 200 20
1 186 167 167 176 172 162 176 170 161 192 187 177 181 179 169 163 167 171 163 171      132 113 117 122 126 118 106 110 109 133 127 123 127 131 12
2 170 167 167 161 157 162 161 159 167 168 158 159 161 153            110 113 117 119 112 118 107 111 119 112 110 123 109 104  
3 196 188 178 182 178 167 172 168 186 186 176 158 154 153            112 116 112 113 120 118 113 111 123 108 106 102 103 104  
4 176 167 171 173 169 165 159 159 165 172 163 161 159 153 149           108 111 113 122 117 109 115 121 117 109 107 107 100 101 97
5 168 166 158 162 159 171 169 163 161 166 152 154 148             109 111 109 112 109 113 115 111 107 107 92 94 91   
6 163 159 171 163 161 159 161 160 159 161 158 136 138 143 140           117 119 121 113 114 109 107 110 107 107 106 88 91 96 92
7 208 201 197 188 178 189 181 183 181 192 186 179 167 159 153 149          146 136 122 132 133 123 119 121 117 132 122 123 119 111 10
8 166 158 171 165 164 167 172 171 168 172 160 146              106 108 106 109 112 114 108 109 113 111 108 102    
9 212 198 211 188 179 192 197 192 194 208 188 186 179 180 178 179 173 183 179       146 138 126 132 126 132 119 122 126 132 137 135 130 126 12
10 186 192 187 177 182 179 183 191 179 192 179 181 176 172 169 176 180 176 169 176 180 176 180 176 170 132 122 119 123 122 110 114 116 123 127 129 123 127 122 11
11 186 176 171 168 159 162 165 172 168 178 166 168 160             120 118 113 109 119 120 117 110 106 110 108 109 104   
12 166 162 158 170 162 158 156 158 148                 110 108 112 108 110 107 106 106 100       
13 176 159 161 166 170 162 158 162 164 154                108 117 112 108 109 110 108 113 110 102      
14 160 166 172 171 167 162 168 170 172 158 149 150 148             112 118 119 118 115 109 110 112 108 112 103 102 93   
15 176 171 178 162 164 160 157 162 160 166 166 162 158 152            123 119 112 109 110 110 113 110 106 108 106 106 111 104  
16 166 162 168 171 168 166 158 156 164 158 162 166 164 162 158 162 156         126 122 119 130 115 112 108 118 124 128 126 118 117 121 11
17 176 164 160 166 158 178 170 167 182 168 158 156 158             112 110 110 112 110 110 109 113 108 106 102     
18 176 172 179 170 163 167 165 174 182 168 162 156              108 112 119 110 107 106 107 108 110 104 106 98    
19 183 176 177 176 178 166 158                   119 113 109 110 114 108 101         
20 166 162 171 167 170 166 167 163 169 161 159 167 158 157            117 113 113 109 110 117 111 112 121 115 111 109 107 103  
 
GROUP - A 
TIME  IN MINUTES AFTER STARTING TREATMENT 
MEAN ARTERIAL PRESSURE (mmHg) MATERNAL HEART RATE (per min) 
 0 20 40 60 80 100 120 140 160 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 0 20 40 60 80 100 120 140 160 180 185 190 195 200 205 210 215 22
1 150 131 134 140 141 133 129 130 126 153 147 141 145 147 137 132 128 131 125 132      87 73 76 78 77 73 78 79 83 74 79 81 82 84 81 87 83 86
2 100 94 134 113 121 133 126 127 135 131 126 128 126 120            87 85 87 89 91 88 87 89 93 93 106 109 111 117     
3 140 106 134 122 139 134 133 128 132 138.3 129 121              81 82 86 87 85 89 87 89 91 89 107 113       
4 131 130 132 119 134 128 130 134 133 135.9 126 123 120             76 77 79 83 82 86 82 81 89 83 93 109 117      
5 129 129 125 129 126 132 131 128 133 127 112               68 71 73 74 72 77 76 69 77 79 97        
6 132 132 138 130 130 126 131 127 124 130 124 104              79 83 81 84 85 85 84 83 79 79 93 99       
7 167 158 134 151 129 128 140 142 138 152 143 142 135 127 124 119          67 69 68 71 73 74 71 77 78 77 90 93 101 102 103 107   
8 155 125 128 128 129 131 129 130 131 131 125 117              82 81 83 87 83 84 84 83 83 81 93 97       
9 159 136 154 151 144 130 133 145 149 157 131 125 146 144 142 144 138 146 139       101 88 88 86 87 91 88 87 88 89 104 99 99 103 100 96 89 93
10 158 145 142 143 139 130 131 140 142 149 146 142 143 139 136 143 141 143 136 143 141 143 141 146 140 91 85 83 89 87 83 89 87 91 98 83 91 89 86 81 87 91 89
11 158 137 132 129 132 130 132 131 127 133 127 129 123             92 88 93 91 87 88 87 84 85 87 97 109 111      
12 129 140 127 129 127 130 123 123 116                 81 83 84 87 91 88 89 90 89          
13 131 139 128 127 129 127 125 129 120 119                76 78 82 83 81 84 85 83 87 86         
14 130 139 137 136 132 127 129 131 129 127 118               86 88 84 89 84 88 89 92 92 91 102        
15 141 136 134 127 131 127 127 127 126 127 79 125 127 121            87 88 82 87 84 86 91 87 82 89 107 110 113 117     
16 139 135 135 144 133 127 125 131 137 127 138 134 133 134 132 131 132         91 89 89 92 90 88 92 93 94 93 97 100 99 100 101 98 101  
17 133 135 127 138 132 133 129 130 133 127 121               90 88 89 88 86 91 90 89 96 95 107        
18 131 135 130 140 126 126 126 130 134 126 125 117              88 87 86 89 90 88 89 90 96 93 112 118       
19 140 135 132 140 135 127 120                   76 77 78 81 82 87 83            
20 133 129 132 128 132 133 130 129 137 130 127 126 124 121            83 87 84 86 90 87 89 90 86 88 106 99 101 107     
 
GROUP - A 
TIME  IN MINUTES AFTER STARTING TREATMENT 
 
RESPIRATORY RATE (per min) URINE OUTPUT (ml)
                           
 0 20 40 60 80 100 120 140 160 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 0 
1 31 30 28 29 28 29 30 28 29 27 28 28 29 30 27 28 29 28 28 29      50 
2 24 23 24 23 25 23 25 23 25 23 24 24 25 23 24 25          150 
3 24 23 24 25 26 24 23 24 25 26 24 25 22 24            100 
4 23 21 22 24 25 23 21 23 24 21 23 22 23 24 23           150 
5 26 24 24 23 26 23 25 26 25 23 23 25 24             200 
6 26 23 26 23 25 26 25 23 23 25 24 25 24 21 23           200 
7 23 21 22 24 25 23 21 23 24 21 23 22 23 24 23           200 
8 23 26 23 25 26 25 23 23 25 24 25 24 21 23 24           200 
9 23 26 23 25 26 25 23 23 25 24 25 24 21 23 24 23 24 26 25       250 
10 23 26 23 25 26 25 23 23 25 24 25 24 21 23 24 23 25 24 25 24 21 23 24 23 24 150 
11 23 26 23 25 26 25 23 23 25 24 25 24 21 23 24           200 
12 26 23 25 26 25 23 23 25 24 25 24               200 
13 23 26 23 25 26 25 23 23 25 24 25 24              150 
14 26 23 25 26 25 23 23 25 24 25 24 23 25             200 
15 23 26 23 25 26 25 23 23 25 24 25 24 21 23 23 24 26         150 
16 26 23 25 26 25 23 23 25 24 25 24 23 25 24 27 25 26         200 
17 23 25 26 25 23 23 25 24 25 24 23 25 27             300 
18 25 26 25 23 23 25 24 25 24 23 25 24 27 25            250 
19 25 24 25 24 23 25 24 27 25                 100 
20 26 25 23 23 25 24 25 24 23 25 24 27 25 27 23 24          100 
 
GROUP - A 
TIME  IN MINUTES AFTER STARTING TREATMENT 
FETAL HEART RATE (per min) PULSE OXIMET
                                        
 0 20 40 60 80 100 120 140 160 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 0 20 40 60 80 100 120 140 160 180 185 190 195 200 
1 132 138 132 144 138 132 138 132 138 126 144 138 132 138 132 144 138 144 138 132      99 99 99 99 99 99 99 99 99 99 99 99 99 99 
2 132 134 144 124 134 144 136 134 134 142 144 136 142 140 128 132          99 99 99 99 99 99 99 99 99 99 99 99 99 99 
3 132 132 138 132 144 138 132 138 132 138 126 144 138 132            99 99 99 99 99 99 99 99 99 99 99 99 99 99 
4 132 138 132 144 138 132 138 132 138 126 144 138 132 134 132           99 99 99 99 99 99 99 99 99 99 99 99 99 99 
5 134 134 144 124 134 144 136 134 134 142 144 136 142             99 99 99 99 99 99 99 99 99 99 99 99 99  
6 132 144 138 132 138 132 138 126 144 138 132 134 132             99 99 99 99 99 99 99 99 99 99 99 99 99  
7 132 138 132 144 138 132 138 132 138 126 144 138 132 134 132 144 136 142        99 99 99 99 99 99 99 99 99 99 99 99 99 99 
8 134 144 124 134 144 136 134 134 142 144 136 142 138 126 144           99 99 99 99 99 99 99 99 99 99 99 99 99 99 
9 132 144 138 132 138 132 138 126 144 138 132 134 132 144 136 142 138 126 144       99 99 99 99 99 99 99 99 99 99 99 99 99 99 
10 132 144 138 132 138 132 138 126 144 138 132 134 132 144 136 142 138 126 144 136 142 138 126 144 138 99 99 99 99 99 99 99 99 99 99 99 99 99 99 
11 144 138 132 138 132 138 126 144 138 132 134 132 144 136 142           99 99 99 99 99 99 99 99 99 99 99 99 99 99 
12 132 138 132 138 126 144 138 132 134 132 144               99 99 99 99 99 99 99 99 99 99 99    
13 144 138 132 138 132 138 126 144 138 132 134 132              99 99 99 99 99 99 99 99 99 99 99 99   
14 144 138 132 138 132 138 126 144 138 132 134 132 144             99 99 99 99 99 99 99 99 99 99 99 99 99  
15 138 132 138 132 138 126 144 138 132 134 132 136 138 134 138 144 128         99 99 99 99 99 99 99 99 99 99 99 99 99 99 
16 132 138 132 138 126 144 138 132 134 132 136 138 134 138 144 128 140         99 99 99 99 99 99 99 99 99 99 99 99 99 99 
17 132 138 126 144 138 132 134 132 136 138 134 138 144             99 99 99 99 99 99 99 99 99 99 99 99 99  
18 144 138 132 138 132 138 126 144 138 132 134 132 144 138            99 99 99 99 99 99 99 99 99 99 99 99 99 99 
19 132 138 132 138 126 144 138 132 134                 99 99 99 99 99 99 99 99 99      
20 138 132 138 132 138 126 144 138 132 134 132 144 138 132 138 144          99 99 99 99 99 99 99 99 99 99 99 99 99 99 
 
GROUP - L 
TIME  IN MINUTES AFTER STARTING TREATMENT 
 
SYSTOLIC BLOOD PRESSURE (mm Hg) DIASTOLIC BLOOD PRESSURE
                                       
 A 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 A 0 5 10 15 20 25 30 35 40 45 50 55 60 65
1 200 190 164 144 140 142 146 142                 120 132 126 111 111 112 108 101       
2 160 161 158 156 161 158 153 156 153 146 141 143             120 119 116 117 117 113 111 110 113 109 107 103   
3 166 172 171 170 168 167 171 173 167 161 158 158 141 142           114 118 121 123 121 119 117 119 119 117 113 116 107 102
4 176 183 181 179 177 181 172 171 171 168 171 167 153 143           118 123 127 125 123 124 121 121 118 121 117 119 111 101
5 166 172 166 158 161 151 146                  107 114 109 111 102 106 99        
6 186 190 182 183 172 177 176 171 168 158 161 153 147 141           112 122 120 117 121 123 117 118 112 111 107 111 109 92
7 200 240 230 200 210 220 210 220 206 200 186 210 180 170 200 210 206 212 198 200 186 180 206  130 140 140 140 140 140 136 140 138 140 136 140 126 126 130
8 176 182 179 177 168 169 163 158 156 156 148              110 116 113 111 120 109 111 109 106 109 102    
9 186 182 176 178 170 166 160 159 163 161 158 157 151 151           126 123 120 118 112 108 109 113 111 109 113 106 106 101
10 176 179 177 182 179 169 171 168 160 159 158 156             116 122 111 114 113 111 109 107 109 111 109 101   
11 176 182 187 170 179 169 177 163 159 161 154 153 151 149           116 122 123 114 113 117 111 113 115 113 107 109 106 101
12 168 176 172 168 163 168 159 156 152 156 152              112 118 119 116 121 112 109 111 108 112 101    
13 200 201 195 189 176 162 169 173 166 159 153              141 136 119 121 132 126 122 117 109 106 101    
14 162 160 158 156 158 151 146                  112 108 109 112 109 111 104        
15 196 202 196 176 172 169 167 171 163 158 146              130 128 123 126 121 119 113 109 107 113 104    
16 220 216 198 190 177 182 170 168 161 158 163 151 143            140 132 128 131 122 118 113 117 121 117 109 106 102  
17 162 164 159 163 161 157 153 151 149                112 114 116 109 107 109 111 107 101      
18 176 178 171 169 162 164 158 163 159 157 153 146             116 122 119 121 118 112 109 107 105 107 109 101   
19 166 172 169 163 159 160 158 153 146 141               108 112 113 109 113 111 107 111 106 91     
20 186 192 187 183 176 173 163 169 158 156 149 141             126 132 121 119 112 119 117 111 109 111 106 103   
 
GROUP - L 
TIME  IN MINUTES AFTER STARTING TREATMENT 
 
MEAN ARTERIAL PRESSURE (mmHg) MATERNAL HEART RATE (per m
                                         
 A 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 A 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 
1 147 151 139 122 121 122 121 115                 96 91 92 93 86 87 86 84         
2 133 133 130 130 132 128 125 125 126 121 118 116             108 101 108 106 102 100 101 97 99 96 92 87     
3 131 136 138 139 137 135 135 137 135 132 128 130 118 115           89 98 97 96 93 91 87 81 83 81 83 82 78 77   
4 137 143 145 143 141 143 138 138 136 137 135 135 125 115           112 101 115 111 109 107 103 101 99 93 96 95 91 87   
5 127 133 128 127 122 121 115                  82 81 79 77 75 71 71          
6 137 145 141 139 138 141 137 136 131 127 125 125 122 108           96 97 95 91 89 87 85 87 83 85 81 79 77 75   
7 153 173 170 160 163 167 161 167 161 160 153 163 145 142 153 161 161 155 145 145 141 147 157  86 84 83 82 84 85 86 86 82 77 82 81 81 84 85 85 
8 132 138 135 133 136 129 128 125 123 125 117              86 92 90 86 85 84 83 81 79 79 77      
9 147 143 139 138 131 127 126 128 128 126 128 123 121 118           146 103 124 116 108 102 98 93 91 87 89 87 85 85   
10 136 141 133 137 135 130 130 127 126 127 125 119             110 101 109 101 96 94 91 94 88 87 83 81     
11 136 142 144 133 135 134 133 130 130 129 123 124 121 118           99 97 90 77 71 69 67 71 71 69 66 67 66 67   
12 131 137 137 133 135 131 126 126 123 130 118              86 91 89 86 87 83 81 83 81 83 84      
13 161 158 144 144 147 139 138 136 128 124 118              96 97 93 97 95 91 92 87 86 81 79      
14 128 125 125 130 125 124 118                  96 99 96 92 90 88 82          
15 152 153 147 143 138 136 131 130 126 128 118              96 99 93 91 87 85 81 83 81 83 80      
16 167 160 151 151 140 139 132 134 134 131 127 121 116            77 79 78 77 75 77 73 77 75 71 70 66 61    
17 129 131 130 127 125 125 125 122 117                82 89 87 82 84 80 79 77 75        
18 136 141 136 137 133 129 125 126 123 124 124 116             96 98 90 88 81 79 77 79 77 75 73 69     
19 127 132 132 127 128 127 124 125 119 108               89 93 89 85 81 79 77 71 69 63       
20 147 152 143 140 133 137 132 130 125 126 120 116             112 101 108 96 90 93 86 81 77 79 71 70     
 
GROUP - L 
TIME  IN MINUTES AFTER STARTING TREATMENT 
 
RESPIRATORY RATE (per min) 
                         
 A 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110
1 24 23 22 23 21 22 23 22 23 21               
2 23 22 22 21 23 23 23 21 22 23 23 23 21 23           
3 27 27 26 25 27 26 25 25 25 25 25 25 26 26 26 27         
4 22 21 20 21 25 23 22 21 23 24 21 21 22 23 22 23         
5 21 21 21 22 21 20 21 20 20 21               
6 23 24 24 23 24 25 23 22 23 24 23 23 23 23 23 22         
7 23 24 23 24 23 21 24 25 25 25 26 25 25 23 24 25 24 24 25 24 24 23 24  
8 24 23 24 22 23 24 23 24 23 24 23 24 24            
9 22 23 24 23 22 23 27 26 25 24 24 23 24 24 26          
10 26 25 26 27 28 26 25 26 25 25 24 24 25 28           
11 27 26 25 27 26 25 25 26 27 27 28 26 27 28 27 26         
12 26 27 26 25 27 28 27 26 27 26 27 26             
13 27 28 27 28 29 27 28 27 28 27 26 27 28            
14 27 25 27 24 26 27 27 26                 
15 24 23 27 26 26 25 27 27 28 29 26 28             
16 28 27 28 29 30 29 29 28 26 25 27 28 29 29           
17 29 30 31 30 25 27 29 29 27 28               
18 28 29 27 26 27 28 29 29 30 29 29 30 29            
19 25 24 25 26 27 26 29 28 29 28 27              
20 28 29 30 31 29 29 28 29 29 28 29 30 29            
 
GROUP - L 
TIME  IN MINUTES AFTER STARTING TREATMENT 
 
 FETAL HEART RATE (per min) PULSE OXIMETRY (%
 A 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 A 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70
1 145 126 144 139 147 130 126 150 149 135               99 99 99 99 99 99 99 99 99 99      
2 134 139 144 126 149 147 138 128 144 146 137 132 133 149           99 99 99 99 99 99 99 99 99 99 99 99 99 99  
3 144 148 139 149 145 135 138 145 138 133 129 142 133 129 139 132         99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
4 133 138 129 126 132 133 128 136 141 143 129 134 137 140 136 128         99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
5 126 130 135 129 135 140 139 137 133 130               99 99 99 99 99 99 99 99 99 99      
6 126 135 130 133 134 139 144 140 138 133 143 130 129 135 136 129 135        99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
7 140 144 148 140 136 132 130 132 130 132 130 134 132 137 136 134 136 133 136 132 128 129 131  99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
8 136 132 136 142 140 136 135 132 131 128 134 136 138 138           99 99 99 99 99 99 99 99 99 99 99 99 99 99  
9 135 134 132 133 136 134 138 142 136 135 134 133 139 139 140          99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
10 135 141 137 139 142 141 142 132 137 136 137 150 143 136 138          99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
11 134 142 136 134 135 136 137 138 135 134 141 143 147 141 136 137 139 136       99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
12 138 146 142 130 137 132 136 132 136 143 142 140             99 99 99 99 99 99 99 99 99 99 99 99    
13 136 138 136 142 141 137 136 140 142 136 142 137 132            99 99 99 99 99 99 99 99 99 99 99 99 99   
14 136 138 137 135 136 132 138 136                 99 99 99 99 99 99 99 99        
15 134 138 140 137 138 135 138 140 142 136 139 139             99 99 99 99 99 99 99 99 99 99 99 99    
16 137 135 140 132 136 140 136 137 135 139 136 138 131 136           99 99 99 99 99 99 99 99 99 99 99 99 99 99  
17 136 132 136 144 138 132 144 144 138 132               99 99 99 99 99 99 99 99 99 99      
18 138 150 144 138 132 138 132 150 144 132 138 132 126            99 99 99 99 99 99 99 99 99 99 99 99 99   
19 132 138 144 138 132 126 126 132 138 132 138              99 99 99 99 99 99 99 99 99 99 99     
20 138 132 126 138 132 138 144 138 132 138 138 132 138            99 99 99 99 99 99 99 99 99 99 99 99 99   
 
 
